EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selective PPARα Modulator Pemafibrate Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Regulation of Leptin Signaling and Remodeling of Gut Microbiota

Koji Yamamoto, Masaru Baba, Akinori Kubo, Ren Yamada, Akihisa Nakamura, Kenichi Morikawa iD, Masatsugu Ohara, Masato Nakai, Takuya Sho, Goki Suda, Koji Ogawa, Ken Furuya und 1 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Koji Yamamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan. Hauptthemen laut MEDLINE: PPAR alpha, Butyrates, Leptin, Benzoxazoles. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease worldwide, and effective pharmacological therapies remain limited. Pemafibrate (Pema), a selective peroxisome proliferator-activated receptor alpha (PPARα) modulator (SPPARMα), has shown promising therapeutic potential in patients with MASLD and hypertriglyceridemia; however, its underlying mechanisms remain incompletely understood. Here, we investigated the therapeutic effects and molecular mechanisms of Pema using in vitro and in vivo MASLD models and evaluated its clinical relevance in patients with MASLD. In a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced MASLD mouse model, Pema dose-dependently ameliorated hepatic steatosis and fibrosis and significantly suppressed the hepatic expression of inflammatory and fibrogenic genes, including TLR4, TNFα, αSMA, and Col1A1. Pema also favorably altered the gut microbiota by increasing the abundance of the phylum Verrucomicrobia, suggesting modulation of the gut–liver axis. In differentiated 3T3-L1 adipocyte-like cells, Pema induced PPARα expression, inhibited insulin-mediated EGR-1 induction, and significantly reduced leptin secretion. Consistent with these findings, serum insulin and leptin levels, as well as the hepatic accumulation of both molecules, were markedly decreased in Pema-treated MASLD mice. Furthermore, in a clinical cohort of 192 patients with MASLD and hypertriglyceridemia, long-term Pema treatment significantly improved liver-related biochemical parameters, insulin resistance, surrogate markers of liver fibrosis, and serum leptin levels. Collectively, these findings demonstrate that Pema attenuates MASLD progression by suppressing leptin-mediated metabolic and inflammatory signaling while improving the gut microenvironment. These results highlight SPPARMα as a promising therapeutic strategy for MASLD and support further clinical investigation of Pema as a disease-modifying treatment targeting the gut–liver axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR alphaButyratesLeptinBenzoxazolesGastrointestinal MicrobiomeFatty LiverAnimalsMiceSignal TransductionMaleHumansLiverDiet, High-Fat3T3-L1 CellsDisease Models, AnimalMice, Inbred C57BL

Stichwörter der Autor:innen

MASLDgut microbiotagut–liver axisleptinpemafibrate

Substanzen

PPAR alphaButyratesLeptin(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidBenzoxazoles

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo 060-8648, Japan.
  • Department of Physiology, Asahikawa Medical University, Asahikawa 078-8510, Japan.
  • Department of Gastroenterology, JCHO Hokkaido Hospital, Sapporo 062-8618, Japan.
  • Keijinkai Maruyama Clinic, Sapporo 064-0820, Japan.
  • Department of Gastroenterology, Sapporo City General Hospital, Sapporo 060-8604, Japan.
  • Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa 070-8530, Japan.

ORCID-Profile: Kenichi Morikawa, Naoya Sakamoto

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • JSPS KAKENHI

Zitieren

APA

Yamamoto, K., Baba, M., Kubo, A., Yamada, R., Nakamura, A., Morikawa, K., Ohara, M., Nakai, M., Sho, T., Suda, G., Ogawa, K., Furuya, K., & Sakamoto, N. (2026). Selective PPARα Modulator Pemafibrate Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Regulation of Leptin Signaling and Remodeling of Gut Microbiota. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177611

Vancouver

Yamamoto K, Baba M, Kubo A, Yamada R, Nakamura A, Morikawa K, et al. Selective PPARα Modulator Pemafibrate Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Regulation of Leptin Signaling and Remodeling of Gut Microbiota. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177611

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Koji and Baba, Masaru and Kubo, Akinori and Yamada, Ren and Nakamura, Akihisa and Morikawa, Kenichi and Ohara, Masatsugu and Nakai, Masato and Sho, Takuya and Suda, Goki and Ogawa, Koji and Furuya, Ken and Sakamoto, Naoya},
  title = {Selective PPARα Modulator Pemafibrate Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Regulation of Leptin Signaling and Remodeling of Gut Microbiota},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177611}
}
Kostenlos starten →